Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dicerna, Flush With Cash, Is Back To The Drawing Board

Executive Summary

The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.

Advertisement

Related Content

Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree
Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree
RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
Novartis RNA pullback gives biotech stocks whiplash
Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098936

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel